New England Retina Consultants

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Macular degeneration6 trials
• Diabetic eye disease1 trial

Phase

• Phase 34 trials
• Phase 21 trial
• Phase 41 trial

Status

• Active, not recruiting6 trials
• Completed1 trial

Lead sponsor

• 4D Molecular Therapeutics2 trials
• EyePoint Pharmaceuticals, Inc.2 trials
• Aviceda Therapeutics, Inc.1 trial
• Genentech, Inc.1 trial
• Hoffmann-La Roche1 trial

Running trials

• Active, not recruiting

  COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

  NCT07449936· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

• Recruiting

  Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

  NCT07064759· Phase 3· 4D Molecular Therapeutics· Source

  Contact: 4DMT Patient Advocacy

• Active, not recruiting

  A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT06795048· Phase 4· Hoffmann-La Roche· Source

• Active, not recruiting

  4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

  NCT06864988· Phase 3· 4D Molecular Therapeutics· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

  NCT06668064· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

• Active, not recruiting

  An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

  NCT05300724· Genentech, Inc.· Source

Closed trials

• Completed

  A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

  NCT05839041· Phase 2· Aviceda Therapeutics, Inc.· Source